ICN Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of SLS Biophile Ltd. and its laser-based, non-ablative wrinkle reduction technology is announced June 28, expanding the drug firm's dermatological franchise. A March 510(k) application is pending at FDA for Swansea, Wales-based SLS Biophile's N-Lite laser treatment system, which has been available in Europe since early this year as an alternative to chemical-based treatments. Financial terms of the deal were not disclosed
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.